Literature DB >> 20848440

Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck.

Kazuaki Chikamatsu1, Goro Takahashi, Koichi Sakakura, Soldano Ferrone, Keisuke Masuyama.   

Abstract

BACKGROUND: CD44 was found as a surface marker in cancer stem cell (CSC) of squamous cell carcinoma of the head and neck (SCCHN); however, the immunologic properties of such CSCs have not yet been elucidated.
METHODS: The immunologic properties of CD44+ cancer stem-like cells were compared with those of CD44- cells using flow cytometry and enzyme-linked immunosorbent assay.
RESULTS: CD44+ cells exhibited weak HLA-A2 and class II expression. Interestingly, downregulation of transporter antigen processing (TAP)2 was found in CD44+ cells. The CD44+ cell population produced significantly higher levels of interleukin (IL)-8, granulocyte colony-stimulating factor (G-CSF), and transforming growth factor (TGF)-β than the CD44- cell population. Moreover, CD44+ cells have been shown to not only more strongly inhibit T-cell proliferation, but also to more efficiently inhibit regulatory T cells (Treg cells) and myeloid-derived suppressor cells (MDSC) as compared with CD44- cells. Additionally, CD44+ cells suppressed Th1 responses and enhanced regulatory T cell responses.
CONCLUSION: CSCs might have higher malignant potential with numerous escape strategies from immune attack.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20848440      PMCID: PMC3426231          DOI: 10.1002/hed.21420

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  39 in total

1.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.

Authors:  M E Prince; R Sivanandan; A Kaczorowski; G T Wolf; M J Kaplan; P Dalerba; I L Weissman; M F Clarke; L E Ailles
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

3.  HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.

Authors:  Takeshi Ogino; Hiroshi Shigyo; Hideyuki Ishii; Akihiro Katayama; Naoyuki Miyokawa; Yasuaki Harabuchi; Soldano Ferrone
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

Review 4.  Myeloid-derived suppressor cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

5.  Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma.

Authors:  Mi-Kyung Kang; Soo-Kyung Kang
Journal:  Stem Cells Dev       Date:  2007-10       Impact factor: 3.272

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  The low rate of HLA class I molecules on the human embryonic stem cell line HS293 is associated with the APM components' expression level.

Authors:  C M Cabrera; A Nieto; J L Cortes; R M Montes; P Catalina; F Cobo; A Barroso-Del-Jesus; A Concha
Journal:  Cell Biol Int       Date:  2007-03-20       Impact factor: 3.612

8.  Development and characterization of gemcitabine-resistant pancreatic tumor cells.

Authors:  Ami N Shah; Justin M Summy; Jing Zhang; Serk In Park; Nila U Parikh; Gary E Gallick
Journal:  Ann Surg Oncol       Date:  2007-10-02       Impact factor: 5.344

9.  Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.

Authors:  Ingo Fricke; Noweeda Mirza; Jakob Dupont; Craig Lockhart; Autumn Jackson; Ji-Hyun Lee; Jeffrey A Sosman; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

10.  Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.

Authors:  Lizzia Raffaghello; Paolo Nozza; Fabio Morandi; Marta Camoriano; Xinhui Wang; Maria Luisa Garrè; Armando Cama; Giuseppe Basso; Soldano Ferrone; Claudio Gambini; Vito Pistoia
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

View more
  37 in total

Review 1.  The biology of head and neck cancer stem cells.

Authors:  Zhaocheng Zhang; Manoel Sant'Ana Filho; Jacques E Nör
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

2.  Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies.

Authors:  Amy S Codd; Saly Al-Taei; Zsuzsanna Tabi
Journal:  Ann Transl Med       Date:  2016-10

Review 3.  Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

Authors:  Yu Lei; Yuying Xie; Yee Sun Tan; Mark E Prince; Jeffrey S Moyer; Jacques Nör; Gregory T Wolf
Journal:  Oral Oncol       Date:  2016-08-21       Impact factor: 5.337

Review 4.  Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.

Authors:  Shannon M Clayton; Joehleen A Archard; Joseph Wagner; D Gregory Farwell; Arnaud F Bewley; Angela Beliveau; Andrew Birkeland; Shyam Rao; Marianne Abouyared; Peter C Belafsky; Johnathon D Anderson
Journal:  Stem Cells Dev       Date:  2020-01-30       Impact factor: 3.272

5.  USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics.

Authors:  Sarah M Russell; Melissa G Lechner; Lucy Gong; Carolina Megiel; Daniel J Liebertz; Rizwan Masood; Adrian J Correa; Jing Han; Raj K Puri; Uttam K Sinha; Alan L Epstein
Journal:  Oral Oncol       Date:  2011-06-29       Impact factor: 5.337

6.  CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.

Authors:  Yunqin Lee; June Ho Shin; Michelle Longmire; Hua Wang; Holbrook E Kohrt; Howard Y Chang; John B Sunwoo
Journal:  Clin Cancer Res       Date:  2016-02-10       Impact factor: 12.531

Review 7.  [Translational approaches in cancer stem cell research].

Authors:  C Mozet; G Wichmann; A Dietz
Journal:  HNO       Date:  2011-09       Impact factor: 1.284

8.  Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer.

Authors:  Ning Chi; Zhaohui Tan; Kewei Ma; Lidao Bao; Zhizhong Yun
Journal:  Int J Clin Exp Med       Date:  2014-10-15

9.  Immunohistochemical location of the p75 neurotrophin receptor (p75NTR) in oral leukoplakia and oral squamous cell carcinoma.

Authors:  Takahiro Kiyosue; Shintaro Kawano; Ryota Matsubara; Yuichi Goto; Mitsuhiro Hirano; Teppei Jinno; Takeshi Toyoshima; Ryoji Kitamura; Kazunari Oobu; Seiji Nakamura
Journal:  Int J Clin Oncol       Date:  2011-12-15       Impact factor: 3.402

10.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.